Bambermycins

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Bambermycins
DrugBank Accession Number
DB11377
Background

Bambermycins are antibiotic complexes which are retrieved from the organism, Streptomyces bambergiensis. They are used as an additive in food ingested by chickens and swine. The bambermycin complex of antibiotics consists primarily of moenomycins A and C.

Type
Small Molecule
Groups
Vet approved
Structure
Weight
Average: 1597.609
Monoisotopic: 1596.660998224
Chemical Formula
C70H109N4O35P
Synonyms
  • Bambermicina
  • Bambermycin
  • Bambermycine
  • Bambermycins
  • Bambermycinum
  • Flavofosfolipol
  • Moenomycin
  • Moenomycin A

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcenocoumarolThe risk or severity of bleeding can be increased when Bambermycins is combined with Acenocoumarol.
AmbroxolThe risk or severity of methemoglobinemia can be increased when Bambermycins is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Bambermycins is combined with Articaine.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Bambermycins.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Bambermycins is combined with Benzocaine.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Gainpro

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as terpene glycosides. These are prenol lipids containing a carbohydrate moiety glycosidically bound to a terpene backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Terpene glycosides
Direct Parent
Terpene glycosides
Alternative Parents
Oligosaccharide phosphates / Fatty acyl glycosides / N-acyl-alpha-hexosamines / Glucuronic acid derivatives / O-glycosyl compounds / Monocyclic monoterpenoids / Dialkyl phosphates / Dicarboxylic acids and derivatives / Pyrans / Oxanes
show 18 more
Substituents
Acetal / Acetamide / Alcohol / Aliphatic heteromonocyclic compound / Alkyl phosphate / Carbamic acid ester / Carbonic acid derivative / Carbonyl group / Carboxamide group / Carboxylic acid
show 37 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
PP922A42V2
CAS number
11015-37-5
InChI Key
FUIOWSNNCWZETH-NAMXWVJMSA-N
InChI
InChI=1S/C70H109N4O35P/c1-31(2)16-14-18-33(4)20-21-34(5)24-26-69(9,10)25-13-12-17-32(3)19-15-27-97-62(92)40(80)29-99-110(95,96)109-67-57(58(108-68(71)93)70(11,94)59(107-67)61(90)91)106-64-45(73-37(8)77)48(83)55(42(102-64)30-98-65-52(87)49(84)46(81)41(28-75)101-65)104-63-44(72-36(7)76)47(82)54(35(6)100-63)103-66-53(88)50(85)51(86)56(105-66)60(89)74-43-38(78)22-23-39(43)79/h13,16,19-20,25,35,40-42,44-59,63-67,75,78,80-88,94H,5,12,14-15,17-18,21-24,26-30H2,1-4,6-11H3,(H2,71,93)(H,72,76)(H,73,77)(H,74,89)(H,90,91)(H,95,96)/b25-13+,32-19+,33-20+/t35-,40-,41-,42-,44-,45-,46-,47-,48-,49+,50+,51-,52-,53-,54-,55-,56+,57-,58-,59-,63+,64+,65-,66-,67-,70+/m1/s1
IUPAC Name
(2S,3S,4R,5R,6R)-4-(carbamoyloxy)-5-{[(2S,3R,4R,5S,6R)-3-acetamido-5-{[(2S,3R,4R,5S,6R)-3-acetamido-4-hydroxy-6-methyl-5-{[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)carbamoyl]oxan-2-yl]oxy}oxan-2-yl]oxy}-4-hydroxy-6-({[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-3-hydroxy-6-({hydroxy[(2R)-2-hydroxy-3-oxo-3-{[(3E,7E,14E)-4,9,9,15,19-pentamethyl-12-methylideneicosa-3,7,14,18-tetraen-1-yl]oxy}propoxy]phosphoryl}oxy)-3-methyloxane-2-carboxylic acid
SMILES
C[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](NC(C)=O)[C@H](O[C@H]3[C@@H](OP(O)(=O)OC[C@@H](O)C(=O)OCC\C=C(/C)CC\C=C\C(C)(C)CCC(=C)C\C=C(/C)CCC=C(C)C)O[C@H](C(O)=O)[C@@](C)(O)[C@@H]3OC(N)=O)O[C@@H]2CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](NC(C)=O)[C@@H](O)[C@@H]1O[C@@H]1O[C@@H]([C@H](O)[C@H](O)[C@H]1O)C(=O)NC1=C(O)CCC1=O

References

General References
  1. Salmon RE, Stevens VI: Effect of bambermycins (Flavomycin) in diets for growing turkeys. Poult Sci. 1990 Jul;69(7):1133-40. [Article]
  2. George BA, Fagerberg DJ: Effect of bambermycins, in vitro, on plasmid-mediated antimicrobial resistance. Am J Vet Res. 1984 Nov;45(11):2336-41. [Article]
  3. Dealy J, Moeller MW: Influence of bambermycins on Salmonella infection and antibiotic resistance in swine. J Anim Sci. 1976 May;42(5):1331-6. [Article]
  4. Dealy J, Moeller MW: Influence of bambermycins on Salmonella infection and antibiotic resistance in calves. J Anim Sci. 1977 May;44(5):734-8. [Article]
  5. Firman JD, Kirn BN: Effects of monensin and bambermycins on the performance of market turkeys. Poult Sci. 1989 Dec;68(12):1724-6. [Article]
  6. Parks CW, Grimes JL, Ferket PR, Fairchild AS: The effect of mannanoligosaccharides, bambermycins, and virginiamycin on performance of large white male market turkeys. Poult Sci. 2001 Jun;80(6):718-23. [Article]
  7. Dealy J, Moeller MW: Effect of bambermycins on Escherichia coli and antibiotic resistance in calves. J Anim Sci. 1977 Dec;45(6):1239-42. [Article]
  8. Hagsten I, Grant RJ, Meade RJ, O'Kelley R: Effect of bambermycins and tylosin on performance of growing-finishing swine. J Anim Sci. 1980 Mar;50(3):484-9. [Article]
  9. Johnston NL, Quarles CL, Fagerberg DJ: Long-term broiler performance with bambermycins and bambermycins plus roxarsone. Poult Sci. 1983 Jul;62(7):1189-94. [Article]
  10. Waldroup PW, Spencer GK, Waibel PE, Quarles CL, Grant RJ: The use of bambermycins (Flavomycin) and halofuginone (Stenorol) in diets for growing turkeys. Poult Sci. 1985 Jul;64(7):1296-301. [Article]
ChemSpider
4938687
RxNav
1367176
Wikipedia
Bambermycin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0755 mg/mLALOGPS
logP1.53ALOGPS
logP-1.8Chemaxon
logS-4.3ALOGPS
pKa (Strongest Acidic)1.58Chemaxon
pKa (Strongest Basic)-4.2Chemaxon
Physiological Charge-3Chemaxon
Hydrogen Acceptor Count31Chemaxon
Hydrogen Donor Count18Chemaxon
Polar Surface Area601.88 Å2Chemaxon
Rotatable Bond Count39Chemaxon
Refractivity376.05 m3·mol-1Chemaxon
Polarizability160.68 Å3Chemaxon
Number of Rings6Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-002v-0112950000-b4a347e53f0f33c43d92
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-06r5-3000090000-85f374c2d1f5abd147ed
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0007-8210390000-e6d7eaab5883a2497269
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0521590000-cf592e1fa5bbebcb0bab
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00r2-4502790000-438d088065ac8118b2a4
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-2412290012-18841f6c9471997b9e22
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at February 25, 2016 18:16 / Updated at February 21, 2021 18:53